FCGR3B and head and neck neoplasm: FCGR3B-targeted drug IMGATUZUMAB was currently being evaluated in clinical trials for colorectal neoplasms, head and neck neoplasms, and non-small-cell lung and PED4D inhibitor was currently being evaluated in clinical trials for Alzheimer’s disease, fragile X syndrome, and depression (Table 2).